Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Polycystic ovary syndrome can be explained as set of symptoms such as insulin sensitivity, menstrual regulatory, infertility, acne, and excess body and facial hair, which occurs due to increased levels of male hormone i.e. androgens in females of child-bearing age (15 to 49 years). 

Statistics:

The global polycystic ovary syndrome treatment market is estimated to account for US$ 945.1 Mn in terms of value and is expected to reach US$ 1,311.0 Mn by the end of 2027.

Global Polycystic Ovary Syndrome Treatment Market: Drivers

High prevalence of polycystic ovary syndrome is expected to propel growth of the global polycystic ovary syndrome treatment market over the forecast period. For instance, according to the study ‘The prevalence of polycystic ovary syndrome in adolescents: A systematic review and meta-analysis’, published in September 2019, the prevalence of polycystic ovarian syndrome in adolescents based on the Rotterdam criteria was 11.04%, based on the National Institute of Health criteria, it was 3.39%, and based on Androgen Excess and Polycystic Ovary Syndrome Society, it was 8.03%.

Moreover, R&D in polycystic ovary syndrome is also expected to aid in growth of the market. For instance, in June 2020, ‘Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis’ – a study funded by the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and National Institute of Diabetes and Digestive and Kidney Diseases reported that polycystic ovary syndrome may have at least two different subtypes.

Statistics:

Insulin Sensitizing Agents held dominant position in the global polycystic ovary syndrome treatment market in 2019, accounting for 32.9% share in terms of value, followed by Aromatase Inhibitors & SERMs and Oral contraceptives, respectively.

Figure 1. Global Polycystic Ovary Syndrome Treatment Market Share (%), by Value, by Drug Class, 2019

Polycystic Ovary Syndrome Treatment  | Coherent Market Insights

Global Polycystic Ovary Syndrome Treatment Market: Restraints

Unavailability of FDA approved drugs is expected to hinder growth of the global polycystic ovary syndrome treatment market. Currently, there are no drugs approved by U.S. FDA and EMA for the direct treatment of polycystic ovary syndrome. Thus, physicians can only prescribe drugs for the management of off-label indications.

Moreover, adoption of alternative treatment options such as Ayurveda and Homeopathy is also expected to hinder growth of the global polycystic ovary syndrome treatment market.

request-sample

Polycystic Ovary Syndrome Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 904.7 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.8% 2027 Value Projection: US$ 1,311.0 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Drug Class: Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs, Diuretics.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, and Sun Pharmaceutical Industries Ltd.

Growth Drivers:
  • High prevalence of polycystic ovary syndrome
  • Research and development
Restraints & Challenges:
  • Unavailability of FDA approved drugs
  • Alternative treatment options

Global Polycystic Ovary Syndrome Treatment Market: Opportunities 

Entry into emerging markets is expected to offer lucrative growth opportunities for players in the global polycystic ovary syndrome treatment market. Pharmaceutical drugs manufacturers may focus on emerging economies in Asia Pacific and Africa to target large patient populations.

Moreover, effective reimbursement policies and reduction in costs is also expected to aid in growth of the market. Drugs used for the treatment of polycystic ovary syndrome are not covered in most coverage policies or health insurance. Cost of few drugs are comparatively high in the U.S. and Europe. Thus, reduction in cost of branded drugs would help the adoption of polycystic ovary syndrome therapeutics across the globe.

The global polycystic ovary syndrome treatment market was valued at US$ 904.7 Mn in 2019 and is forecast to reach a value of US$ 1,311.0 Mn by 2027 at a CAGR of 4.8% between 2020 and 2027.

Figure 2. Global Polycystic Ovary Syndrome Treatment Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Polycystic Ovary Syndrome Treatment  | Coherent Market Insights

Market Trends/Key Takeaways

High prevalence of polycystic ovary syndrome in emerging economies is expected to propel growth of the global polycystic ovary syndrome treatment market over the forecast period. For instance, according to the review article, Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India, published in 2019, the prevalence of polycystic ovary syndrome in India ranges from 3.7 to 22.5 percent.

Moreover, R&D in polycystic ovary syndrome is also expected to aid in growth of the market. For instance, in April 2019, a study published in The Journal of Clinical Endocrinology & Metabolism reported identifying DENND1A, a gene involved in male hormone production, which plays a major role in the development of polycystic ovary syndrome.

Global Polycystic Ovary Syndrome Treatment Market: Competitive Landscape

Major players operating in the global polycystic ovary syndrome treatment market include, Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., and Crinetics Pharmaceuticals, Inc.

Global Polycystic Ovary Syndrome Treatment Market: Key Developments

Major players in the global polycystic ovary syndrome treatment market are focused on adopting partnership strategies to expand their product portfolio. For instance, in January 2020, Evotec SE and Bayer AG announced the expansion of their partnership in women's health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome.

Polycystic ovary syndrome can be explained as set of symptoms such as insulin sensitivity, menstrual regulatory, infertility, acne, and excess body and facial hair, which occurs due to increased levels of male hormone i.e. androgens in females of child-bearing age (15 to 49 years). Polycystic ovary syndrome is an incurable diseases, however, it can be managed by various options such as lifestyle changes, reducing weight, and taking medicines.

Restraints of the Global Polycystic Ovary Syndrome Treatment Market

Major factors hampering the growth of the polycystic ovary syndrome treatment market during the forecast period constitutes of unavailability of FDA approved drugs, and alternative treatment options.

Key features of the study:

  • This report provides in-depth analysis of the global polycystic ovary syndrome treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global polycystic ovary syndrome treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck & Co., Inc., AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., and Crinetics Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global polycystic ovary syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Polycystic Ovary Syndrome Treatment Market, By Drug Class:
    • Oral contraceptives
    • Insulin Sensitizing Agents
    • Anti-Depressants
    • Ornithine Decarboxylase Inhibitors
    • Aromatase Inhibitors & SERMs
    • Diuretics
  • Global Polycystic Ovary Syndrome Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Polycystic Ovary Syndrome Treatment Market, By Geography:
    • North America
      • By Drug Class
        • Oral contraceptives
        • Insulin Sensitizing Agents
        • Anti-Depressants
        • Ornithine Decarboxylase Inhibitors
        • Aromatase Inhibitors & SERMs
        • Diuretics
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Class
        • Oral contraceptives
        • Insulin Sensitizing Agents
        • Anti-Depressants
        • Ornithine Decarboxylase Inhibitors
        • Aromatase Inhibitors & SERMs
        • Diuretics
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class
        • Oral contraceptives
        • Insulin Sensitizing Agents
        • Anti-Depressants
        • Ornithine Decarboxylase Inhibitors
        • Aromatase Inhibitors & SERMs
        • Diuretics
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Class
        • Oral contraceptives
        • Insulin Sensitizing Agents
        • Anti-Depressants
        • Ornithine Decarboxylase Inhibitors
        • Aromatase Inhibitors & SERMs
        • Diuretics
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Drug Class
        • Oral contraceptives
        • Insulin Sensitizing Agents
        • Anti-Depressants
        • Ornithine Decarboxylase Inhibitors
        • Aromatase Inhibitors & SERMs
        • Diuretics
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class
        • Oral contraceptives
        • Insulin Sensitizing Agents
        • Anti-Depressants
        • Ornithine Decarboxylase Inhibitors
        • Aromatase Inhibitors & SERMs
        • Diuretics
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Sanofi Plc*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Novartis AG
    • Teva Pharmaceutical Industries Limited
    • Addex Therapeutics Ltd.
    • BIOCAD
    • Merck & Co., Inc.
    • AstraZeneca plc.
    • Bristol Myers Squibb Co.
    • Ferring Pharmaceuticals, Inc.
    • Crinetics Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis
  4. Global Polycystic Ovary Syndrome Treatment Market, By Drug Class, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Oral contraceptives
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Insulin Sensitizing Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Anti-Depressants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Ornithine Decarboxylase Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Aromatase Inhibitors & SERMs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Diuretics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Polycystic Ovary Syndrome Treatment Market, By Distribution Channel, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Polycystic Ovary Syndrome Treatment Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • Sanofi Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Limited
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Addex Therapeutics Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • BIOCAD
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AstraZeneca plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bristol Myers Squibb Co.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Ferring Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Crinetics Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 33 market data tables and 23 figures on “Polycystic Ovary Syndrome Treatment Market – Global forecast to 2027.

Frequently Asked Questions

The global polycystic ovary syndrome treatment market was valued at US$ 904.7 Mn in 2019 and is forecast to reach a value of US$ 1,311.0 Mn by 2027 at a CAGR of 4.8% between 2020 and 2027.
Major factor driving the growth of global polycystic ovary syndrome treatment market during the forecast period include high prevalence of polycystic ovary syndrome, and research and development.
Major factors hampering the growth of the polycystic ovary syndrome treatment market during the forecast period constitutes of unavailability of FDA approved drugs, and alternative treatment options.
Insulin sensitizing agents held dominant position in the global polycystic ovary syndrome treatment market in 2019.
North America polycystic ovary syndrome treatment market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck & Co., Inc., AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., and Crinetics Pharmaceuticals, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner